A Single Institution Experience Of Egfr Inhibitors In Patients With Advanced Squamous Cell Anal Carcinomas (Scac).

623 Background: Although SCAC are relatively rare, their incidence has been increasing steadily. Because of limited data, treatment of metastatic disease is a major therapeutic challenge. Recent data has demonstrated a low rate of KRAS and EGFR mutations, suggesting a potential target of EGFR inhibitors. In this study, we report the safety and efficacy of EGFR inhibitors in patients (pts) with advanced SCAC. Methods: A retrospective analysis was conducted using the Moffitt Cancer tumor registry from 1/2009 to 1/2014. Eligible pts had advanced SCAC and received an EGFR inhibitor as part of their treatment. Results: 13 pts were identified for analysis. Median age was 59 years (range: 41-68). All pts received concurrent chemoradiation (Nigro regimen) as initial treatment and subsequently had recurrence. Upon diagnosis of recurrent disease, 5 pts received 2 lines of systemic chemotherapy, 5 pts received 1 line and 3 did not receive any treatment prior to receiving EGFR inhibitors. 5 pts received single agent ...